Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM TAK
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in September Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS